References
- WHO Coronavirus (COVID-19) Data; 2023. Available from: https://covid19.who.int. Accessed July 24, 2023.
- Gusev E, Sarapultsev A, Hu D, et al. Problems of Pathogenesis and Pathogenetic Therapy of COVID-19 from the Perspective of the General Theory of Pathological Systems (General Pathological Processes). Int J Mol Sci. 2021;22(14):7582. doi:10.3390/ijms22147582
- Gusev E, Sarapultsev A, Solomatina L, et al. SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19. Int J Mol Sci. 2022;23(3):1716. doi:10.3390/ijms23031716
- Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–154. doi:10.1038/s41579-020-00459-7
- Chilamakuri R, Agarwal S. COVID-19: characteristics and Therapeutics. Cells. 2021;10(2):206. doi:10.3390/cells10020206
- Dhawan M, Priyanka, Parmar M, et al. Convalescent plasma therapy against the emerging SARS-CoV-2 variants: delineation of the potentialities and risks. Int J Surgery. 2022:97. doi:10.1016/j.ijsu.2021.106204
- Zhang X, Xi L, Pang F, et al. Convalescent plasma in the treatment of severe covid-19: a systematic review and meta-analysis. Iran J Public Health. 2020. doi:10.18502/ijph.v49i11.4716
- Priyanka, Chopra H, Choudhary OP. mRNA vaccines as an armor to combat the infectious diseases. Travel Med Infect Dis. 2023;52. doi:10.1016/j.tmaid.2023.102550
- Fang E, Liu X, Li M, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7(1):56.
- Choudhary OP, Priyanka, Ahmed JQ, et al. Heterologous prime-boost vaccination against COVID-19: is it safe and reliable? Human Vaccines Immunotherapeutics. 2021;17(12):5135–5138. doi:10.1080/21645515.2021.2007015
- Ahmed JQ, Maulud SQ, Dhawan M, et al. MicroRNAs in the development of potential therapeutic targets against COVID-19: a narrative review. J Infect Public Health. 2022;15(7):788–799. doi:10.1016/j.jiph.2022.06.012
- ZHeng JQ, Chen BM, Zhang JX. Chinese Medicine Practice Guidelines for COVID-19 in Malaysia (3rd Trial Version). J Beijing Unv Traditional Chine Med. 2021;44(09):784–788.
- National Health Commission of the People’s Republic of China. Protocol for the Treatment of COVID-19 (the 9th Trial Version); 2022. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88tp:shtml. Accessed April 1, 2022.
- Liang YH. The Study of Relationship Between Characteristic of Climate Changes in Malaysia with Syndrome Type of Disease Caused by Six Evil in Externally Contracted Heat Disease. Guangzhou University of Chinese Medicine; 2013.
- Li JS, Feng ZZ, Chun L, et al. Diagnosis Standard of Traditional Chinese Medicine Syndromes for Coronavirus Disease 2019 (Trial). J Traditional Chine Med. 2021;62(01):86–90. doi:10.13288/j.11-2166/r.2021.01.020
- Li JS, Feng ZZ, Chun L, et al. Research Progress of Etiology and Syndrome Differentiation of Traditional Chinese Medicine of Corona Virus Disease 2019. Liaoning J Traditional Chine Med. 2022;49(02):213–216. doi:10.13192/j.issn.1000-1719.2022.02.056
- Li JL, Yang JL, Zhou HL, et al. Mechanism of sovereign medicines in Sanren Decoction on COVID-19 based on network pharmacology and molecular docking. Chine Traditional Herbal Drugs. 2020;51(09):2345–2353.
- Yang YY, Li QW, Bao TT, et al. Syndrome Differentiation and Treatment of COVID-19 by Academician Tong Xiaolin: origin, Innovation, and Development of “Cold-Dampness Plague” Theory. World Chine Med. 2021;17:1–6.
- Zhang P, Wang C, Zou JB, et al. Investigation on Mechanism and Active Components of Hanshizufei Formula Treating COVID-19 Based on Network Pharmacology and Molecular Docking. Pharmacol Clin Chine Materia Medica. 2020;36(05):38–44. doi:10.13412/j.cnki.zyyl.20200727.001
- Zong Y, Zhao KH. Analysis of Corona Virus Disease 2019 in the field of epidemic disease of TCM. Pharm Clin Chine Materia Medica. 2021;12(01):30–32+37.
- Traditional Chinese Medicine Bureau of Guangdong Province. Protocol for the Treatment of COVID-19 of Guangdong Province; 2022. Available from: http://szyyj.gd.gov.cn/zwgk/gsgg/content/post_2902010.html. Accessed April 1, 2022.